Hospital Pierre Wertheimer

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Epilepsy4 trials
• Alzheimer disease3 trials
• Glioblastoma3 trials
• Multiple sclerosis3 trials
• Parkinson disease2 trials
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 trial
• Migraine1 trial
• Tourette syndrome1 trial

Phase

• Phase 310 trials
• Phase 23 trials
• Phase 2/33 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Completed8 trials
• Active, not recruiting6 trials
• Recruiting4 trials

Lead sponsor

• Hoffmann-La Roche3 trials
• Xenon Pharmaceuticals Inc.3 trials
• AbbVie2 trials
• ACADIA Pharmaceuticals Inc.2 trials
• Global Coalition for Adaptive Research1 trial
• and 7 more

Running trials

• Enrolling by invitation

  ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

  NCT06194799· Phase 3· ACADIA Pharmaceuticals Inc.· Source

• Recruiting

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

  NCT05716100· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Enrolling by invitation

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  NCT05667142· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Recruiting

  Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT05327114· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

  NCT05123703· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

  NCT05109728· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

  NCT04544449· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

  NCT03970447· Phase 2/3· Global Coalition for Adaptive Research· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy3 recruiting
• Alzheimer disease1 recruiting

Closed trials

• Active, not recruiting

  Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

  NCT06315751· Phase 2· Noema Pharma AG· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source

• Completed

  Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine

  NCT05748483· Phase 3· AbbVie· Source

• Completed

  A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC OLE)

  NCT05604170· Phase 3· Marinus Pharmaceuticals Inc.· Source

• Completed

  A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression

  NCT03779230· Phase 1/2· Philogen S.p.A.· Source

• Completed

  A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

  NCT05318976· Phase 2· Inmune Bio, Inc.· Source

• Completed

  Open-label Trial in Parkinson's Disease (PD)

  NCT04760769· Phase 3· AbbVie· Source

• Active, not recruiting

  A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

  NCT02726386· Phase 2· NeuroDerm Ltd.· Source